When a publication of Harvard Business Review’s caliber prints something, it stands as fact unless an authoritative voice corrects it. Therefore, I feel obligated to comment on Christopher Bowe’s recent HBR article, “Fixing Pharma’s Incentives Problem in the Wake of the U.S. Opioid Crisis.” I’m disappointed in (although hardly surprised by) the misleading content of…